Quality -of-life scores ( Piper Fatigue Scale MD 0.73 , 95 % CI 0.29 to 1.18 ; I2 = 0 % ; studies = 3 ) and peak oxygen consumption ( MD 2.77 mL/kg/min , 95 % CI -0.89 to 6.43 ; I2 = 36 % ; 2 studies , 32 participants ) were associated with very low- quality evidence , and we remain uncertain about the role of intravenous iron for these metrics .
Current evidence is insufficient to show benefit of intravenous iron preparations for the treatment of non-anaemic iron deficiency across a variety of patient population s , beyond stating that it may result in a small , clinical ly insignificant increase in haemoglobin concentration .
BACKGROUND Iron deficiency is one of the most common nutritional deficiencies , and has a number of physiological manifestations .
Early , or non-anaemic iron deficiency can result in fatigue and diminished exercise capacity .
Oral iron preparations have a high incidence of intolerable side effects , and are ineffective in certain forms of iron deficiency .
Consequently , intravenous iron preparations are increasingly used in the treatment of non-anaemic iron deficiency .
The newer , more stable iron preparations in particular purport to have a lower incidence of side effects , and are now used across a range of different patient population s. OBJECTIVES To assess the effects of intravenous iron therapy in the treatment of adults with non-anaemic iron deficiency .
Effect of iron injections on aerobic-exercise performance of iron-depleted female athletes.
This investigation examined the effect of intramuscular iron injections on aerobic-exercise performance in iron-deficient women . Sixteen athletes performed a 10-min steady-state submaximal economy test , a VO2max test , and a timed test to exhaustion at VO2max workload . Subjects were r and omly assigned to an iron-supplemented group ( IG ) receiving intramuscular iron injections or to a placebo group ( PG ) . Twenty days after the first injection , exercise and blood testing were repeated . A final blood test occurred on Day 28 . Post supplementation , no differences were found between the groups ' submaximal or maximal VO2 , heart rate , or blood lactate ( P > 0.05 ) . Time to exhaustion was increased in the IG ( P < 0.05 ) but was not greater than that of the PG ( P > 0.05 ) . The IG 's serum ferritin ( SF ) was significantly increased on Days 20 and 28 ( mean + /- st and ard error : 19 + /- 3 to 65 + /- 11 to 57 + /- 12 microg/L ; P < 0.01 ) , with a percentage change from baseline significantly greater than in the PG ( P < 0.01 ) . It was concluded that intramuscular iron injections can effectively increase SF without enhancing submaximal or maximal aerobic-exercise performance in iron-depleted female athletes
Quality -of-life scores ( Piper Fatigue Scale MD 0.73 , 95 % CI 0.29 to 1.18 ; I2 = 0 % ; studies = 3 ) and peak oxygen consumption ( MD 2.77 mL/kg/min , 95 % CI -0.89 to 6.43 ; I2 = 36 % ; 2 studies , 32 participants ) were associated with very low- quality evidence , and we remain uncertain about the role of intravenous iron for these metrics .
Current evidence is insufficient to show benefit of intravenous iron preparations for the treatment of non-anaemic iron deficiency across a variety of patient population s , beyond stating that it may result in a small , clinical ly insignificant increase in haemoglobin concentration .
BACKGROUND Iron deficiency is one of the most common nutritional deficiencies , and has a number of physiological manifestations .
Early , or non-anaemic iron deficiency can result in fatigue and diminished exercise capacity .
Oral iron preparations have a high incidence of intolerable side effects , and are ineffective in certain forms of iron deficiency .
Consequently , intravenous iron preparations are increasingly used in the treatment of non-anaemic iron deficiency .
The newer , more stable iron preparations in particular purport to have a lower incidence of side effects , and are now used across a range of different patient population s. OBJECTIVES To assess the effects of intravenous iron therapy in the treatment of adults with non-anaemic iron deficiency .